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  pathophysiological mechanism for PTSD that surveyed studies of 
both pharmacological manipulations and non-pharmacological 
stress challenges concluded that there was insufﬁ  cient evidence to 
support any of the models advanced so far to implicate HPA axis 
dysfunction in PTSD (de Kloet et al., 2006).
A mechanistic possibility that has received relatively little 
investigative attention is hyposensitivity to adrenocorticotropin 
(ACTH) at the level of the adrenal cortex, which could explain both 
subnormal circulating cortisol concentrations and compensatory 
upregulation of CNS corticotropin-releasing factor (Kanter et al., 
2001). However, Rasmusson et al. (2001) found that patients with 
PTSD produce more cortisol in response to the standard clinical 
250 µg ACTH stimulation test than controls. The supraphysiologi-
cal dose of ACTH used in this test, which was designed to be a 
clinical indicator of adrenal insufﬁ  ciency, provides an index of the 
adrenal’s maximal secretory capability, but is of very limited value 
in gauging the responsiveness of the adrenal to submaximal, physi-
ological concentrations of ACTH.
Therefore, to examine adrenocortical responsiveness to physi-
ological stimulation in PTSD patients, we performed a pilot study 
to determine doses of ACTH that would stimulate a low to mod-
erate cortisol response and one that would reﬂ  ect a high level of 
stress but remain within the physiological range. On the basis of 
the pilot study we administered placebo and two doses of ACTH 
(1.5 and 7.5 ng/kg body weight) to PTSD patients and control 
participants. We hypothesized that in response to administration 
of low dose exogenous ACTH, cortisol concentrations of PTSD 
INTRODUCTION
Attribution of relationships between posttraumatic stress disorder 
(PTSD) and hypothalamic–pituitary–adrenocortical (HPA) dys-
function is intuitively apposite because of the importance of the 
HPA axis in the mediation of stress responses, and several early 
studies of PTSD reported HPA dysregulation (Smith et al., 1989; 
Yehuda et al., 1990, 1991, 1993; Hockings et al., 1993). However, 
from the beginning, consistency in the speciﬁ  cs of these ﬁ  ndings 
has been lacking. Low plasma or serum cortisol has been the most 
frequently observed HPA abnormality in PTSD (Yehuda, 2002), 
but a large number of studies have failed to ﬁ  nd decreased circulat-
ing cortisol (Meewisse et al., 2007). A recent meta-analysis found 
that across 37 studies, 828 people with PTSD and 800 controls 
did not differ in cortisol levels (Meewisse et al., 2007). However, 
cortisol levels were lower in PTSD patients than in controls not 
exposed to trauma. The meta-analysis indicated that an associa-
tion of PTSD with low cortisol is most likely to be observed when: 
(a) women are included in the study, (b) cortisol is sampled in 
the afternoon near its circadian nadir, and (c) the PTSD is the 
result of physical or sexual abuse. A variety of speciﬁ  c mechanisms 
and loci of HPA dysregulation have been suggested to explain low 
cortisol in PTSD (de Kloet et al., 2006). The currently prevailing 
model argues for enhanced negative feedback of the HPA axis by 
cortisol. This viewpoint has been supported by several studies 
(Yehuda et al., 1995, 2002, 2004a,b, 2006b; Newport et al., 2004) 
but not by others (Kanter et al., 2001; Kellner et al., 2004; Lindley 
et al., 2004). A review of the experimental evidence for a speciﬁ  c 
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participants would increase less than the cortisol concentrations 
of control participants, reﬂ  ecting adrenal hyposensitivity to ACTH 
in PTSD.
Circulating levels of dehydroepiandrosterone (DHEA) have 
also been investigated in connection with PTSD. DHEA, and its 
sulfated form, DHEA sulfate (DHEAS), are secreted by the human 
adrenal cortex in concentrations greater than cortisol, and their 
secretion is also stimulated by ACTH. However, they are secreted 
from a different adrenocortical zone than cortisol, are differentially 
regulated, and display biological actions that may oppose those of 
cortisol (Albertson et al., 1984; Kimonides et al., 1999; Muller et al., 
2006; Rainey and Nakamura, 2008). Discordance among DHEA, 
DHEAS, and cortisol secretion has often been reported (Grifﬁ  ng 
et al., 1985; Baulieu, 1996; Rainey and Nakamura, 2008), as well 
as differences in their relationships to PTSD (Spivak et al., 2000; 
Yehuda et al., 2006a; Bremner et al., 2007; Gill et al., 2008). In an 
earlier study we found plasma DHEA concentrations to be lower 
in male PTSD patients than in male control subjects (Kanter et al., 
2001). In other studies, DHEA in PTSD has generally been reported 
to be either unchanged (Pico-Alfonso et al., 2004; Rasmusson 
et al., 2006; Bremner et al., 2007) or higher than normal (Spivak 
et al., 2000; Rasmusson et al., 2004; Yehuda et al., 2006a; Gill et al., 
2008). Based on our earlier results, we hypothesized that DHEA 
 concentrations of PTSD participants would increase less than those 
of control participants in response to administration of physi-
ological doses of ACTH.
MATERIALS AND METHODS
SUBJECTS
This study was approved by the institutional review board at 
the University of Washington, and all subjects provided written 
informed consent. All subjects underwent a medical history, screen-
ing physical examination, 12-lead electrocardiogram, and screening 
laboratory tests of blood samples for electrolytes, glucose, blood 
urea nitrogen, creatinine, serum glutamic oxaloacetic transaminase, 
serum glutamic pyruvic transaminase, thyroid function tests, and 
complete blood count, and of urine samples for routine urinalysis, 
urine toxicology screen, and for female subjects of childbearing 
potential, urine pregnancy test.
Use of any psychoactive medication or any medication known 
to affect the HPA axis within 2 weeks of the study was exclusion-
ary for all subjects. These medications included antidepressants, 
antipsychotics, anticonvulsants, tranquilizers, sedative/hypnotics, 
antihypertensives, and oral or inhaled glucocorticoids. The only 
medications taken by participants in the study were ibuprofen, 
the antihistamines cetirizine and loratadine, and glucosamine and 
chondroitin for treatment of osteoarthritis.
Participants taking medications to treat PTSD were withdrawn 
from those medications, under medical supervision, for up to 30 
days. The period required for withdrawal was dependent on the 
biological half-life of each medication and management of poten-
tial withdrawal symptoms.
Female subjects of childbearing potential underwent urine 
pregnancy tests on each study day to ensure that no pregnant par-
ticipants were exposed to ACTH. Female subjects of childbearing 
potential agreed to use a non-hormonal barrier form of birth con-
trol for the period of the study. Hormonal contraceptives were not 
allowed for at least 3 months prior to the study because of their 
stimulation of corticosteroid-binding globulin (CBG) that results 
in elevated levels of total plasma cortisol.
The inclusion criteria for participants in the PTSD group were: 
(a) meeting DSM-IV diagnostic criteria for PTSD based on admin-
istration of the Structured Clinical Interview for DSM-IV (SCID) – 
Patient Edition (First et al., 1995); (b) a Clinician-Administered 
PTSD scale (CAPS) score ≥65 (Blake et al., 1990, 1995); (c) a Life 
Event History (LEH) scale score of ≥1 (Kessler et al., 1995); (d) a 
Mississippi Scale for Combat-Related Posttraumatic Stress Disorder 
score of ≥111 (or ≥107 on the civilian version) (Keane et al., 1988); 
(e) an Impact of Event Total Scale score ≥50 (Weiss and Marmar, 
1997); (f) a Posttraumatic Stress Diagnostic Scale score ≥34 (Foa, 
1995); and (g) a PTSD Checklist score ≥50 (Weathers et al., 1993; 
Blanchard et al., 1996; Weathers and Ford, 1996). Control subjects 
were administered the SCID – Nonpatient Edition and the LEH. To 
conﬁ  rm the participants’ self-report of never having been exposed 
to trauma, an LEH scale score of 0 was required for inclusion in 
the control group.
All participants were free of current (past 6 months) acute 
or chronic Axis I psychiatric disorders (with the exception of 
PTSD in the PTSD subject group) based on SCID assessment. 
Two control and one PTSD subject had past histories of depres-
sion. Absence of substance abuse within 3 months of the study 
by subject report and urine toxicology screen was required. One 
control and seven PTSD subjects had a past history of alcohol 
abuse, and one individual in each group had a history of alcohol 
dependence. Two control and one PTSD participant had past 
histories of substance abuse (cannabis). One subject in each group 
was a current smoker; no information about past smoking his-
tory was requested.
Participants included nine PTSD subjects: eight males with 
combat trauma PTSD and one female with civilian trauma PTSD, 
50.3 ± 2.5 years old [mean ± standard error of the mean (SEM)]. 
There were nine healthy non-trauma exposed aged-matched con-
trols: six males and three females, 41.2 ± 3.5 years old. The ages of 
the two groups did not differ signiﬁ  cantly. The PTSD participants 
had moderately severe symptoms according to the CAPS (total 
CAPS score = 76.7 ± 6.0).
ACTH INFUSION
For each participant, the three study infusions were performed 
on different days, separated by at least 1 week, in the Clinical 
Research Unit of the Veterans Affairs Puget Sound Health Care 
System, Seattle Division. Participants were instructed to abstain 
from alcohol on the evening prior to each study session, to eat a 
normal breakfast (or at least a snack and liquid) before 10:00 am. 
Subjects were instructed not to eat or drink and not to smoke after 
10:00 am and to arrive at the VA Special Studies Unit by noon. The 
two smokers were allowed to wear a nicotine patch. The 1.5 and 
7.5 ng/kg doses of ACTH1–24 (Cortrosyn®, Organon) and placebo 
(normal saline) were administered in a random, counterbalanced 
manner on the three separate study days. The study room was 
quiet and free of stimuli that might precipitate PTSD symptoms. 
Subjects were maintained in a supine position and an intrave-
nous (IV) catheter was placed in the antecubital vein of each arm; 
one catheter was used for infusion of ACTH or placebo, and the Frontiers in Behavioral Neuroscience  www.frontiersin.org  October 2009  | Volume 3  |  Article 40  |  3
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other, for blood draws. The IV lines were kept patent with a slow 
(50 ml/h)   infusion of normal saline. We obtained baseline blood 
samples 30 and 35 min following the placement of the IV catheters. 
Forty minutes (time 0) after catheter placement, the study drug for 
the given day was administered via IV bolus push (<30 s). All infu-
sions were begun by 1:00 pm. The afternoon study time was selected 
because the circadian rhythms of circulating ACTH and cortisol 
rhythms undergo a rapid concentration decline in the morning. 
By early afternoon the levels of both hormones provide a relatively 
low, ﬂ  at, and stable baseline, particularly in the absence of a mid-
day meal, which is typically followed by a postprandial hormonal 
spike (Van Cauter et al., 1992).
Subjects, but not investigators, were blind to the study condi-
tion. ACTH was diluted in normal saline in order to measure the 
small doses precisely, and the IV line was ﬂ  ushed thoroughly after 
ACTH administration.
BLOOD COLLECTION AND HORMONAL MEASUREMENTS
Blood samples were collected every 5 min for 60 min following 
ACTH administration and then every 15 min for the next 90 min. 
Blood was collected into chilled tubes containing ethylenediami-
netetraacetic acid; the tubes were placed on ice until processed. 
The samples were cold-centrifuged within 1 h of collection. The 
plasma was aliquoted and stored at −80°C until assayed. For each 
hormone, all samples from a given subject were included in a single 
assay, and each assay contained samples from an equal number of 
subjects from each group.
Plasma ACTH concentration was measured with DSL-2300 
ACTH RIA Kits according to the manufacturer’s protocol (Diagnostic 
Systems Laboratories, Webster, TX, USA). The method was chosen 
because the ACTH antibody has 100% cross-reactivity with the 
infused ACTH1–24, thus allowing an accurate measurement of total 
circulating ACTH (ACTH1–24 and endogenous ACTH1–39 combined). 
The intra- and inter-assay coefﬁ  cients of variation are 6.0 and 7.0%, 
respectively, and the minimum detection limit is 3.5 pg/ml.
Cortisol was measured by radioimmunoassay in unextracted 
plasma. Samples were diluted with phosphate buffer and heated for 
20 min at 80°C to denature binding globulins. Cortisol antiserum 
was obtained from ICN Biomedicals (Costa Mesa, CA, USA). The 
detection limit for cortisol is 0.5 mg/dl. Intra- and inter-assay coef-
ﬁ  cients of variation are 4.6 and 10.2%, respectively.
Plasma concentrations of DHEA were measured with the 
DSL-8900 DHEA Radioimmunoassay Kit (Diagnostic Systems 
Laboratories, Webster, TX, USA) following the manufacturer’s 
protocol. Cross-reactivity of the antiserum with DHEA-sulfate 
is 0.02%, and cross-reactivities with other steroids are all <1%. 
Sensitivity of the assay is 0.03 ng/ml. The intra- and inter-assay 
coefﬁ  cients of variation are 2.8 and 5.9%, respectively.
STATISTICAL ANALYSIS
The effects of subject group and ACTH dose on the magnitude 
and time-course of the cortisol and DHEA responses were deter-
mined using the concentration values at each time point minus the 
baseline values (response delta) by analysis of variance (ANOVA) 
for repeated measures followed by Fisher’s protected least sig-
niﬁ  cant difference (PLSD) post hoc test for paired comparisons. 
Areas under the response curves (AUCs) of the three groups were 
  compared by ANOVA. Correlations between PTSD symptom 
severity and cortisol and DHEA measures were determined by 
linear regression.
RESULTS
ANOVA for repeated measures for the effect of participant diagnosis 
on the baseline levels of each of the three hormones (two baseline 
samples at each of three sessions) showed no differences in ACTH or 
DHEA concentrations between groups, but signiﬁ  cantly higher cir-
culating cortisol levels in the PTSD group (F5,52 = 4.2, p = 0.046).
There were no adverse effects of the ACTH infusion. At the peak 
of ACTH concentration (5 min after infusion in both groups and 
for both ACTH doses), there was a highly signiﬁ  cant effect of dose 
(F1,48 = 34.7, p < 0.0001) on the change in circulating ACTH relative to 
baseline (ACTH delta). Paired comparisons of the ACTH deltas of the 
three treatment conditions with Fisher’s PLSD also indicated highly 
signiﬁ  cant separation between placebo, 1.5 and 7.5 ng/kg conditions 
(Figure 1). There was no signiﬁ  cant group effect or group–dose inter-
action, demonstrating that the infusions produced comparable levels 
of circulating ACTH in both groups. The change in ACTH plasma 
concentration following the higher dose (115.8 ± 16.6 pg/ml) was 
more than threefold greater than that following the low dose ACTH 
infusion (34.8 ± 6.6). Delta ACTH was slightly negative for the pla-
cebo condition (−5.1 ± 12). The area under the curve of the plasma 
ACTH concentration was calculated for the ﬁ  rst six sampling times 
(30 min) after the infusion during which ACTH concentration rap-
idly rises to a peak and falls to baseline again. ANOVA of the AUC 
showed a highly signiﬁ  cant effect of dose (F2,48 = 21.4, p < 0.0001), 
but no signiﬁ  cant group or interaction effects.
There were signiﬁ  cant dose-related differences in the  magnitude 
of the cortisol responses to the ACTH injections in both groups of 
subjects (effect of dose on cortisol AUC: F2,48 = 19.7, p < 0.0001). 
However, neither the cortisol response delta nor the area under the 
cortisol response curve differed between subject groups at either 
dose, and there was no group–dose interaction (Figure 2).
ANOVA for repeated measures for delta DHEA concentration 
showed no effect of subject group (F1,48 = 0.004, p = 0.95) on delta 
DHEA, although there were highly signiﬁ  cant dose (F2,48 = 6.2, 
p < 0.005), time and time–dose interaction effects (both p < 0.001) 
(Figure 3). The area under the DHEA dose-response curve 
increased from 11.7 ± 5.8 after the placebo infusion to 15.5 ± 6.4 
after the 1.5 ng/kg dose ACTH infusion to 31.8 ± 10.7 after the 
7.5 ng/kg dose. However, due to high variability in the DHEA 
responses to ACTH, there were no signiﬁ  cant effects of dose or sub-
ject group on the DHEA AUC. The ANOVA of the AUC of the ratio 
of circulating cortisol to DHEA was highly signiﬁ  cant (F2,48 = 12.5, 
p < 0.0001), consistent with the ﬁ  nding of a pronounced dose effect 
on cortisol. There was no group or group by dose effect on the 
cortisol/DHEA ratio.
PTSD symptom severity, as measured by baseline CAPS total 
scores, did not correlate signiﬁ  cantly with the increases in corti-
sol or DHEA. After the lower dose of ACTH, the correlations of 
cortisol and DHEA AUCs with symptom severity as measured by 
CAPS total scores were r = −0.47, p = 0.21 and r = −0.10, p = 0.79, 
respectively. After infusion with the higher dose, the correlations 
of CAPS scores with cortisol and DHEA were r = −0.27, p = 0.49 
and r = 0.31, p = 0.42, respectively.Frontiers in Behavioral Neuroscience  www.frontiersin.org  October 2009  | Volume 3  |  Article 40  |  4
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FIGURE 1 | Plasma ACTH concentration in PTSD and control subjects after ACTH infusion. Sampling occurred at 5-min intervals for 60 min and at 15-min 
intervals for the following 90 min. Mean and SEM values are plotted for each subject group and each dose of ACTH for the ﬁ  rst 45 min after infusion during the 
dynamic portion of the ACTH concentration proﬁ  le.
FIGURE 2 | Plasma cortisol concentration in PTSD and control subjects after ACTH infusion. Sampling occurred at 5-min intervals for 60 min and at 15-min intervals 
for the following 90 min. Mean and SEM values are plotted for each subject group and each dose of ACTH for the entire 150-min sampling period after infusion.Frontiers in Behavioral Neuroscience  www.frontiersin.org  October 2009  | Volume 3  |  Article 40  |  5
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DISCUSSION
Our primary ﬁ  nding was that cortisol and DHEA responses to 
physiological doses of ACTH did not differ signiﬁ  cantly between 
PTSD and control participants. This result suggests that   adrenal 
function and responsiveness to ACTH are normal in PTSD and 
that if indeed, HPA dysregulation is a concomitant of PTSD, 
the locus of the functional deﬁ  cits is not at the level of the 
adrenal cortex.
The peak ACTH concentrations achieved after the higher of 
our two doses (7.5  ng/kg) were approximately 150–250  pg/ml, 
which are comparable to those reached after administration of 
the standard insulin tolerance test to control subjects (plasma 
glucose concentration ≤2.2 mmol/l)  (Radikova et  al., 2006) or 
after exhaustive exercise (Farrell et al., 1983; Inder et al., 1998). 
Extreme stresses such as severe sepsis or multiple trauma (Vermes 
et al., 1995) are required to elicit increases in ACTH concentra-
tion (∼350–800 pg/ml) similar to the peak levels observed after the 
clinical 1 µg “low-dose” ACTH test (∼550–800 pg/ml) (Gerritsen 
and Vermes, 1997). The ACTH levels (∼4000–5800 pg/ml) resulting 
from the standard clinical 250 µg test are much higher yet (Raff 
and Findling, 1989). The 250 µg dose (∼3,570 ng/kg for a 70-kg 
subject), is over 475 times greater than the higher of the two doses 
used in the present study.
Our results differ from those of Rasmusson and colleagues 
(Rasmusson et al., 2001, 2004) who found that cortisol concen-
trations of PTSD patients rose signiﬁ  cantly more than those of 
control participants following injection of 250 µg of ACTH. The 
dose of ACTH administered is one of several methodological 
differences that may explain these conﬂ  icting results. Several 
researchers have noted that standard clinical high-dose ACTH 
administration, and even the 1 µg “low-dose” (approximately 
14.3 ng/kg for a 70-kg individual) ACTH challenge test maxi-
mally stimulate ACTH receptors. These doses provide a valid 
index of maximal adrenocortical capacity to respond to ACTH 
but do not measure the sensitivity of the adrenal cortex to 
stimulation by ACTH in the normal physiological range (Thaler 
and Blevins Jr., 1998; Arvat et al., 2000; Tordjman et al., 2000; 
Rasmusson et al., 2001).
There are also multiple differences in the characteristics of the 
study populations of the Rasmusson studies (Rasmusson et al., 
2001, 2004, 2006) and the current study that make comparisons 
difﬁ  cult. The participants in the Rasmusson studies were all pre-
menopausal women, whereas the subjects in the current study were 
predominantly male, but included some female participants. All 
but one of the participants in the Rasmusson studies had been 
victims of civilian sexual trauma, whereas all but one of the PTSD 
patients in the current study had experienced combat trauma. The 
Rasmusson PTSD groups included some participants with comor-
bid diagnoses of major depressive disorder, obsessive compulsive 
disorder, dysthymia, or generalized anxiety disorder. We excluded 
subjects with Axis I diagnoses other than PTSD. The Rasmusson 
studies also included subjects taking oral contraceptives, which 
result in signiﬁ  cant elevations in total plasma cortisol responses to 
ACTH due to increased liver production of CBG (Gozansky et al., 
FIGURE 3 | Plasma DHEA concentration of PTSD and control subjects after ACTH infusion. Sampling occurred at 5-min intervals for 60 min and at 15-min 
intervals for the following 90 min. Mean and SEM values are plotted for each subject group and each dose of ACTH for the ﬁ  rst 45 min after infusion.Frontiers in Behavioral Neuroscience  www.frontiersin.org  October 2009  | Volume 3  |  Article 40  |  6
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2005; Šimunková et al., 2008). In the ﬁ  rst study (Rasmusson et al., 
2001), four of the PTSD subjects and none of the controls were 
taking oral contraceptives, which may have contributed to greater 
plasma cortisol responses associated with PTSD.
The DHEA results of the present study are consistent with 
the conclusion drawn from the cortisol data that adrenocortical 
responses to physiological concentrations of ACTH are normal 
in PTSD. However, most studies have found elevated DHEA to 
be associated with PTSD (Maninger et al., 2009), and injection of 
250 µg ACTH elicited signiﬁ  cantly higher DHEA concentrations in 
PTSD than in control subjects (Rasmusson et al., 2004).
We did not measure DHEAS in the current study and can-
not speculate about DHEAS-related changes in PTSD. There 
is a tendency in some review articles to combine DHEA and 
DHEAS data as if the concentrations of the two steroids reﬂ  ected 
similar reactions to stimuli. However, DHEA and DHEAS are 
differentially regulated, ﬂ  uctuations in their circulating levels 
are discordant (Baulieu, 1996; Chen and Parker Jr., 2004), and 
their concentrations have been shown not to change in tan-
dem in PTSD patients (Bremner et al., 2007; Olff et al., 2007). 
Circulating DHEA concentrations undergo circadian oscillations 
coincidentally with cortisol, but because of its low metabolic 
clearance rate (MCR), DHEAS remains at approximately the 
same concentrations throughout the day and is much less sus-
ceptible to stress-related perturbations (Baulieu, 1996). DHEAS 
has a half-life of 7–10 h as opposed to the 15–30 min half-life of 
DHEA, and a MCR of 5–20 L/day compared to approximately 
2,000 L/day for DHEA.
The dissimilarity in the observed effects of ACTH administra-
tion on DHEA and cortisol between the Rasmusson study and 
this study may reﬂ  ect differences in ACTH dose, inclusion/exclu-
sion criteria, gender, and/or the nature of the precipitating trauma. 
Generalizations from the present study may be limited by the 
relatively small number of subjects and the inclusion of a mixed 
gender study population, although gender differences in human 
adrenal responsiveness to physiological doses of ACTH have not 
been demonstrated. Serum cortisol responses to eight ACTH doses 
from 0.01 to 250 µg did not differ signiﬁ  cantly between men and 
women (Arvat et al., 2000). However, gender differences occur in 
other aspects of human HPA function, and gender effects in the 
present study cannot be ruled out. Consistent effects of gender 
on free cortisol responses to speciﬁ  c stressors have been reported 
(Seeman et al., 2001; Kudielka et al., 2009), and estrogens stimulate 
hepatic production of CBG, resulting in elevated levels of total 
plasma cortisol in women (Wilkinson et al., 2001). In addition, 
sensitivity to glucocorticoid feedback inhibition differs between 
men and women in the morning (Wilkinson et al., 1997), but not in 
the evening (Wilkinson et al., 2001). Therefore, to test the possibil-
ity that the absence of an effect of PTSD on adrenal responsiveness 
observed here was the result of an interaction of gender and PTSD, 
additional statistical analyses were carried out using data from male 
subjects only (not shown), yielding an n of 8 in the PTSD group 
and 6 in the control group. There were no signiﬁ  cant group differ-
ences in plasma ACTH concentration in the dynamic phase during 
the ﬁ  rst 30 min after infusion, and no signiﬁ  cant group effects 
or group–dose interactions on ACTH, cortisol or DHEA AUC as 
determined by ANOVAs.
The absence of signiﬁ   cant differences between PTSD and 
control participants in cortisol and DHEA responses to physi-
ological levels of ACTH suggests that abnormalities in adrenal 
responsiveness are unlikely to be a major factor in PTSD-related 
alterations in HPA axis function. Thus, future research on the 
  neuroendocrinology of PTSD may be more successfully directed 
toward detailed   examination of central mechanisms such as 
enhanced negative feedback of the HPA axis by cortisol or altera-
tion of glucocorticoid or mineralocorticoid receptor function or 
number. Studies of glucocorticoid feedback in PTSD have seldom 
made explicit reference to the three discrete time domains and 
mechanisms of inhibition that have been demonstrated (Keller-
Wood and Dallman, 1984; Posener et al., 1997; Posener et al., 
1998). However, the possibility exists that differences in feedback 
inhibition between PTSD and control subjects may be restricted 
to, or more pronounced in, a single time domain. To our knowl-
edge only two studies have investigated fast feedback inhibition 
in PTSD, one ﬁ  nding increased feedback in PTSD (Yehuda et al., 
2006b) and one ﬁ  nding no group differences (Kanter et al., 2001). 
Other studies have focused on slow feedback, generally using dex-
amethasone suppression of ACTH secretion.
It is unlikely that fast feedback affected the magnitude of the 
cortisol response to ACTH infusion in the present study. Peak circu-
lating cortisol concentrations were reached between 15 and 30 min 
post-injection. Glucocorticoid fast feedback inhibition results in 
signiﬁ  cant decreases in endogenous ACTH levels within 15–30 min 
in both rats and humans, but because of the much longer half-life 
of cortisol and corticosterone, circulating glucocorticoid concen-
trations are not reduced by fast feedback in either species within 
30 min (Liberzon et al., 1997; Boscaro et al., 1998).
The diversity of the ﬁ  ndings related to HPA dysfunction and 
the variation in the history and comorbidity of the subject popu-
lations in various studies suggests that HPA dysfunction may not 
be a necessary concomitant of PTSD and that the existence of 
dysfunction or the speciﬁ  c locus of the dysfunction may vary as 
a function of differing types or intensities of traumatic experi-
ence. Variations in circulating concentrations of adrenocortical 
steroids, alterations of glucocorticoid feedback inhibition, modi-
ﬁ  cations of adrenal responsiveness, or other changes in HPA axis 
function, when they occur in conjunction with PTSD, may be 
characteristic responses to speciﬁ  c constellations of the nature 
and frequency of the trauma, gender, age, genetic susceptibility, 
and individual history.
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